• 1
    Smith DA, van de Waterbeemd H, Walker DK. Inter-species scaling. In: Pharmacokinetics and Metabolism in Drug Design, eds Smith DA, van de Waterbeemd H, Walker DK, Mannhold R, Kubinyi H, Timmerman H. Weinheim, New York, Chichester, Brisbane, Singapore, Toronto: Wyley VCH publishers, 2001; 12332.
  • 2
    Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. Pharmacokinet Biopharm 1982; 10: 20127.
  • 3
    Ings RM. Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 1990; 20: 120131.
  • 4
    Lave T, Coassolo P, Reigner B. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin Pharmacokinetet 1999; 36: 21131.
  • 5
    Gardner IB, Walker DK, Lennard MS, Smith DA, Tucker GT. Comparison of the disposition of two novel combined thromboxane synthase inhibitors/thromboxane A2 receptor antagonists in the isolated perfused rat liver. Xenobiotica 1995; 25: 18597.
  • 6
    Rajman I. PK/PD modelling and simulations: utility in drug development. Drug Discov Today 2008; 13: 3416.
  • 7
    Thygesen P, Macheras P, van Peer A. Physiologically-based PK/PD modelling of therapeutic macromolecules. Pharm Res 2009; 12: 254350.
  • 8
    Schmidt S, Barbour A, Sahre M, Rand KH, Derendorf H. PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol 2008; 5: 54956.
  • 9
    Hunt JA. Cholesteryl ester transfer protein (CETP) inhibitors. Curr Top Med Chem 2009; 9: 41927.
  • 10
    Parini P, Rudel LL. Is there a need for cholesteryl ester transfer protein inhibition? Arterioscler Thromb Vasc Biol 2003; 23: 3745.
  • 11
    Stein EA, Roth EM, Rhyne JM, Burgess T, Kallend D, Robinson JG. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010; 31: 4808.
  • 12
    Kumar S, Tan EY, Hartmann G, Biddle Z, Bergman AJ, Dru J, Ho JZ, Jones AN, Staskiewicz SJ, Braun MP, Karanam B, Dean DC, Gendrano IN, Graves MW, Wagner JA, Krishna R. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. Drug Metab Dispos 2010; 38: 47483.
  • 13
    Kuo GH, Rano T, Pelton P, Demarest KT, Gibbs AC, Murray WV, Damiano BP, Connelly MA. Design, synthesis, and biological evaluation of (2R,alphaS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor. J Med Chem 2009; 52: 176872.
  • 14
    Weber O, Bischoff H, Schmeck C, Boettcher MF. Cholesteryl ester transfer protein and its inhibition. Cell Mol Life Sci 2010; 67: 313949.
  • 15
    Schmeck C, Gielen-Haertwig H, Vakalopoulos A, Bischoff H, Li V, Wirtz G, Weber O. Novel tetrahydrochinoline derived CETP-inhibitors. Bioorg Med Chem Lett 2010; 20: 17403.
  • 16
    Boettcher FM, Heinig R, Schmeck C, Ludwig M, Schaefer A, Gelfert-Peukert S, Wensing G, Weber O. Single dose pharmacokinetics, pharmacodynamics, tolerability, and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP). Br J Clin Pharmacol 2011 this issue.
  • 17
    Dinchuk J, Hart J, Gonzalez G, Karmann G, Schmidt D, Wirak DO. Remodelling of lipoproteins in transgenic mice expressing human cholesteryl ester transfer protein. Biochim Biophys Acta 1995; 1255: 30110.
  • 18
    Schuhmacher J, Buehner K, Witt-Laido A. Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins. J Pharm Sci 2000; 89: 100821.
  • 19
    Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 146979.
  • 20
    Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283: 4658.
  • 21
    Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a ‘well-stirred’ model and a ‘parallel tube’ model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 1977; 5: 62553.
  • 22
    Bisgaier CL, Minton LL, Essenburg AD, White A, Homan R. Use of fluorescent cholesteryl ester microemulsions in cholesteryl ester transfer protein assays. J Lipid Res 1993; 34: 162534.
  • 23
    Edginton AN, Schmitt W, Willmann S. Application of physiology-based pharmacokinetic and pharmacodynamic modeling to individualized target-controlled propofol infusions. Adv Ther 2006; 23: 14358.
  • 24
    Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiology-based pharmacokinetic (PBPK) model for children. Clin Pharmacokinet 2006; 45: 101334.
  • 25
    Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. Development of a physiology-based population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 2007; 34: 40131.
  • 26
    Willmann S, Edginton AN, Dressman JB. Development and validation of a physiology-based model for the prediction of oral absorption in monkeys. Pharm Res 2007; 24: 127582.
  • 27
    Vossen M, Sevestre M, Niederalt C, Jang I-J, Willmann S, Edginton AN. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theor Biol Med Model 2007; 26: 413.
  • 28
    Edginton AN, Theil P, Schmitt W, Willmann S. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 2008; 4: 114352.
  • 29
    Edginton AN, Willmann S. Physiology-based simulations of pathological conditions: pharmacokinetic variability associated with liver cirrhosis. Clin Pharmacokinet 2008; 47: 74352.
  • 30
    Edginton AN, Ahr G, Willmann S, Stass S. Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modeling. Clin Pharmacokinet 2009; 48: 1817.
  • 31
    Willmann S, Edginton AN, Kleine-Besten M, Jantratid E, Thelen K, Dressman JB. Whole-body physiologically-based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption. J Pharm Pharmacol 2009; 61: 8919.
  • 32
    Willmann S, Edginton AN, Coboeken K, Ahr G, Lippert J. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clin Pharmacol Ther 2009; 68: 63443.
  • 33
    Willmann S, Lippert J, Sevestre M, Solodenko J. Fois F, Schmitt W. PK-Sim®: a physiologically based pharmacokinetic ‘whole-body’ model. Biosilico 2003; 1: 1214.
  • 34
    Willmann S, Lippert J, Schmitt W. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol 2005; 1: 15968.
  • 35
    Willmann S, Thelen K, Becker C, Dressman JB, Lippert J. Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs. Eur J Pharm Biopharm 2010; 76: 8394.
  • 36
    Thelen K, Jantratid E, Dressman JB, Willmann S. Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing. J Pharm Sci 2010; 99: 2899904.
  • 37
    Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman JB. A physiological model for the estimation of fraction of dose absorbed in humans. J Med Chem 2004; 47: 402231.
  • 38
    Willmann S, Schmitt W, Keldenich J, Dressman JB. A physiologic model for simulating gastro-intestinal flow and drug absorption in rats. Pharm Res 2003; 20: 176671.
  • 39
    Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004; 24: 4907.
  • 40
    Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350: 150515.
  • 41
    Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML, RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356: 162030.
  • 42
    Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM, ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 130416.
  • 43
    Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 210922.
  • 44
    Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ, RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007; 370: 15360.
  • 45
    Joy T, Hegele RA. The end of the road for CETP inhibitors after torcetrapib? Curr Opin Cardiol 2009; 24: 36471.
  • 46
    Neeli H, Rader DJ. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? Cardiol Clin 2008; 26: 53746.